


Primary endpoint: Proportion of patients achieving PASI 75 at Week 16.
Secondary endpoint: PASI 50 rates and the proportion of patients achieving a PGA2 score of 0–1


Eligibility: Aged 18–80 years; PASI ≥12; static PGA ≥3; chronic moderate-to-severe plaque psoriasis for ≥6 months; BSA involvement ≥10%

TRIAL DESIGN

Patients randomized 3:3:3:2



Patients were evaluated: Every 2 weeks for efficacy and safety; at Week 16 for the primary and secondary endpoints; at Week 32 for secondary endpoints.
*dose titrated over 6 days



The phase III COMFORT-1 trial met its primary endpoint for the 3 mg BID dose of piclidenoson (superiority over placebo in PASI 75 at Week 16). Both doses of piclidenoson were well-tolerated up to 32 weeks.

Abbreviations: BID, twice daily; mITT, modified intention-to-treat population; PASI 75, 75% improvement in Psoriasis Area and Severity; Index; PDI, Psoriasis Disability Index; PGA2, Physician’s Global Assessment 2; pic, piclidenoson; TEAE, treatment-emergent adverse event.

Papp KA, et al. *J Eur Acad Dermatol Venereol*. 2024. Online ahead of print. DOI: 10.1111/jdv.19811